ClinicalTrials.gov
public full text
Public Domain
Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology
The purpose of the study is to test the safety and tolerability of twice daily Verdiperstat in patients with semantic variant primary progressive aphasia (svPPA) due to frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP). Three-fourths of the participants will receive Verdiperstat and one-fourth will receive Placebo during the 24-week treatment duration.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia#1125632
- Multi-task learning for the automatic grading of enlarged perivascular space burden using MRI#1141709
- A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors#862657
- ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial#807053
- Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age#426672
Record · ID 1173157
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive